Enanta Pharmaceuticals Inc (ENTA)

42.80
1.10 2.40
NASDAQ : Health Care
Prev Close 43.85
Open 43.60
Day Low/High 42.49 / 43.60
52 Wk Low/High 16.75 / 51.89
Volume 77.78K
Avg Volume 202.60K
Exchange NASDAQ
Shares Outstanding 19.09M
Market Cap 852.19M
EPS 1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2017

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Enanta Announces U.S. FDA Approval Of AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) In As Little As 8 Weeks

Enanta Announces U.S. FDA Approval Of AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) In As Little As 8 Weeks

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

Enanta Announces European Commission Grants AbbVie Marketing Authorization For MAVIRET® (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Announces European Commission Grants AbbVie Marketing Authorization For MAVIRET® (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the European...

European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- MAVIRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*

Enanta Pharmaceuticals To Host Conference Call On August 7 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2017

Enanta Pharmaceuticals To Host Conference Call On August 7 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2017

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Interesting ENTA Put And Call Options For August 18th

Investors in Enanta Pharmaceuticals Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ENTA options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Enanta Announces New Data On EDP-938, A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV), At The XIX International Symposium On Respiratory Viral Infections

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data on EDP-938,...

AbbVie Receives CHMP Positive Opinion For MAVIRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)(1)*

Enanta Announces That AbbVie Receives CHMP Positive Opinion For MAVIRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the European...

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Enanta Announces Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates In Challenging-to-Treat Genotype 3 Chronic HCV Patients

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported that AbbVie announced...

Enanta Announces 99 Percent SVR12 Rate In Chronic HCV Patients With Compensated Cirrhosis Treated With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that 99 percent...

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis

- New data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment(1)

Commit To Purchase Enanta Pharmaceuticals At $25, Earn 9.1% Annualized Using Options

Investors considering a purchase of Enanta Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $30.83/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Enanta Announces New Preclinical Data On Its FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) And Primary Biliary Cholangitis (PBC) At The International Liver Congress™ 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data from its lead...

Enanta Pharmaceuticals To Host Conference Call On May 8 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Second Quarter Ended March 31, 2017

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Enanta Pharmaceuticals Announces Data Presentations At The International Liver Congress™ 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that several abstracts...

Enanta Pharmaceuticals To Present At The H.C. Wainwright 1st Annual NASH Investor Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Announces Japanese Ministry Of Health, Labour And Welfare Grants Priority Review For AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that priority review...

AbbVie Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

- Priority review granted in Japan, following EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively

Enanta Announces CHMP Grants Positive Opinion For An Eight-Week Treatment Option With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today that the Committee for...

AbbVie Receives CHMP Positive Opinion For Eight-Week Treatment Option With VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C

- CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis*

Oversold Conditions For Enanta Pharmaceuticals (ENTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Announces U.S. FDA Grants Priority Review To AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

Enanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes (GT1-6) Of Chronic Hepatitis C

Enanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes (GT1-6) Of Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that AbbVie's...

Enanta Pharmaceuticals To Host Conference Call On February 8 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals To Host Conference Call On February 8 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

TheStreet Quant Rating: C- (Hold)